Literature DB >> 26815287

Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases.

Sarthak Gupta1, Ioanna P Tatouli2, Lindsey B Rosen3, Sarfaraz Hasni4, Ilias Alevizos5, Zerai G Manna4, Juan Rivera4, Chao Jiang4, Richard M Siegel4, Steven M Holland3, Haralampos M Moutsopoulos2, Sarah K Browne3.   

Abstract

OBJECTIVE: Anticytokine autoantibodies occur across a range of hematologic, pulmonary, and infectious diseases. However, systematic investigation of their presence and significance in autoimmune diseases is lacking. This study was undertaken to examine the distinct functions of anticytokine autoantibodies in patients with systemic lupus erythematosus (SLE) compared to patients with other rheumatic diseases and healthy controls.
METHODS: Serum samples from patients with SLE (n = 199), patients with primary Sjögren's syndrome (SS) (n = 150), patients with rheumatoid arthritis (RA) (n = 149), and healthy controls (n = 200) were screened for 24 anticytokine autoantibodies using a multiplex bead-based assay. To evaluate the biologic activity of anticytokine autoantibodies, their ability to block cytokine-induced signal transduction or protein expression was measured. RNA sequencing was performed on whole blood in a subset of healthy controls and patients with SLE.
RESULTS: Patients with SLE and those with SS had a striking excess of autoantibodies against interferons and the interferon-responsive chemokine interferon-inducible protein 10 (IP-10). Only autoantibodies against type I interferon, interleukin-12 (IL-12), and IL-22 exhibited neutralizing activity. In SLE, the presence of anti-interferon-γ autoantibodies was correlated with more severe disease activity, higher levels of anti-double-stranded DNA antibodies, and elevated expression of interferon-α/β-inducible genes. Conversely, in SLE patients with blocking anti-interferon-α autoantibodies, the type I interferon gene expression signature was normalized. Anti-type III interferon autoantibodies (λ2, λ3) and anti-IP-10 autoantibodies were newly recognized in SLE patient serum, and autoantibodies against macrophage-colony stimulating factor, IL-4, IL-7, IL-17, and IL-22, none of which have been previously identified in rheumatic conditions, were discovered.
CONCLUSION: Anticytokine autoantibodies are associated with distinct patterns of disease in SLE, SS, and RA. Anti-interferon autoantibodies are overrepresented in patients with SLE and those with SS, and fall into distinct functional classes, with only a subset of anti-type I interferon antibodies exhibiting neutralizing activity. Anti-interferon-γ autoantibodies are correlated with increased disease activity and interferon-related gene expression, suggesting that such autoantibodies may contribute to the pathogenesis of SLE.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26815287      PMCID: PMC5391258          DOI: 10.1002/art.39607

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  48 in total

1.  Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

Authors:  Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland
Journal:  Blood       Date:  2012-03-08       Impact factor: 22.113

2.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

3.  An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Authors:  M S Kavuru; A Malur; I Marshall; B P Barna; M Meziane; I Huizar; H Dalrymple; R Karnekar; M J Thomassen
Journal:  Eur Respir J       Date:  2011-04-08       Impact factor: 16.671

4.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

5.  Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.

Authors:  Ryushi Tazawa; Bruce C Trapnell; Yoshikazu Inoue; Toru Arai; Toshinori Takada; Yasuyuki Nasuhara; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masayuki Hojo; Haruyuki Ishii; Masanori Yokoba; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Yoshiko Tsuchihashi; Konosuke Morimoto; Masanori Akira; Masaki Terada; Junji Otsuka; Masahito Ebina; Chinatsu Kaneko; Toshihiro Nukiwa; Jeffrey P Krischer; Kohei Akazawa; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2010-02-18       Impact factor: 21.405

6.  Interferon alpha treatment of patients with impaired interferon gamma signaling.

Authors:  H I Bax; A F Freeman; L Ding; A P Hsu; B Marciano; E Kristosturyan; T Jancel; C Spalding; J Pechacek; K N Olivier; L A Barnhart; L Boris; C Frein; R J Claypool; V Anderson; C S Zerbe; S M Holland; E P Sampaio
Journal:  J Clin Immunol       Date:  2013-03-20       Impact factor: 8.317

7.  Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus.

Authors:  Yihong Yao; Brandon W Higgs; Chris Morehouse; Melissa de Los Reyes; Wendy Trigona; Philip Brohawn; Wendy White; Jianliang Zhang; Barbara White; Anthony J Coyle; Peter A Kiener; Bahija Jallal
Journal:  Hum Genomics Proteomics       Date:  2009-11-17

8.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

9.  The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity.

Authors:  A N Theofilopoulos; S Koundouris; D H Kono; B R Lawson
Journal:  Arthritis Res       Date:  2001-02-14

Review 10.  Microarray analysis of gene expression in lupus.

Authors:  Mary K Crow; Jay Wohlgemuth
Journal:  Arthritis Res Ther       Date:  2003-10-13       Impact factor: 5.156

View more
  39 in total

1.  Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism.

Authors:  Sarthak Gupta; Shuichiro Nakabo; Luz P Blanco; Liam J O'Neil; Gustaf Wigerblad; Rishi R Goel; Pragnesh Mistry; Kan Jiang; Carmelo Carmona-Rivera; Diana W Chan; Xinghao Wang; Hege L Pedersen; Manasi Gadkari; Katherine N Howe; Faiza Naz; Stefania Dell'Orso; Sarfaraz A Hasni; Caeden Dempsey; Ashley Buscetta; Pamela A Frischmeyer-Guerrerio; Paul Kruszka; Maximilian Muenke; Luis M Franco; Hong-Wei Sun; Mariana J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

2.  Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.

Authors:  Bethany D Harris; Srilalitha Kuruganti; Ashlesha Deshpande; Paul A Goepfert; W Winn Chatham; Mark R Walter
Journal:  Lupus       Date:  2020-07-01       Impact factor: 2.911

3.  Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore.

Authors:  H S Howe; B Y H Thong; K O Kong; H H Chng; T Y Lian; F L Chia; K S S Tay; T C Lau; W G Law; E T Koh; B P Leung
Journal:  Clin Exp Immunol       Date:  2017-05-02       Impact factor: 4.330

4.  Detection of Neutralizing Anti-Type 1 Interferon Autoantibodies.

Authors:  Elana R Shaw; Lindsey B Rosen; Li Ding; Steven M Holland; Helen C Su
Journal:  Curr Protoc       Date:  2022-08

5.  Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Authors:  Adrian Gervais; Tom Le Voyer; Jérémie Rosain; Quentin Philippot; Jérémy Manry; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Shohei Eto; Marina Garcia-Prat; Lucy Bizien; Alba Parra-Martínez; Rui Yang; Liis Haljasmägi; Mélanie Migaud; Karita Särekannu; Julia Maslovskaja; Evangelos Vandreakos; Olivier Hermine; Aurora Pujol; Pärt Peterson; Trine H Mogensen; Lee Rowen; James Mond; Xavier de Lamballerie; Xavier Duval; France Mentré; Marie Zins; Pere Soler-Palacin; Roger Colobran; Guy Gorochov; Xavier Solanich; Sophie Susen; Javier Martinez-Picado; Didier Raoult; Marc Vasse; Peter K Gregersen; Lorenzo Piemonti; Carlos Rodríguez-Gallego; Luigi D Notarangelo; Helen C Su; Kai Kisand; Satoshi Okada; Anne Puel; Emmanuelle Jouanguy; Charles M Rice; Pierre Tiberghien; Qian Zhang; Aurélie Cobat; Laurent Abel; Jean-Laurent Casanova; Paul Bastard; Nicolas de Prost; Yacine Tandjaoui-Lambiotte; Charles-Edouard Luyt; Blanca Amador-Borrero; Alexandre Gaudet; Julien Poissy; Pascal Morel; Pascale Richard; Fabrice Cognasse; Jesus Troya; Sophie Trouillet-Assant; Alexandre Belot; Kahina Saker; Pierre Garçon; Jacques G Rivière; Jean-Christophe Lagier; Stéphanie Gentile; Lindsey B Rosen; Elana Shaw; Tomohiro Morio; Junko Tanaka; David Dalmau; Pierre-Louis Tharaux; Damien Sene; Alain Stepanian; Bruno Megarbane; Vasiliki Triantafyllia; Arnaud Fekkar; James R Heath; José Luis Franco; Juan-Manuel Anaya; Jordi Solé-Violán; Luisa Imberti; Andrea Biondi; Paolo Bonfanti; Riccardo Castagnoli; Ottavia M Delmonte; Yu Zhang; Andrew L Snow; Steven M Holland; Catherine Biggs; Marcela Moncada-Vélez; Andrés Augusto Arias; Lazaro Lorenzo; Soraya Boucherit; Boubacar Coulibaly; Dany Anglicheau; Anna M Planas; Filomeen Haerynck; Sotirija Duvlis; Robert L Nussbaum; Tayfun Ozcelik; Sevgi Keles; Ahmed A Bousfiha; Jalila El Bakkouri; Carolina Ramirez-Santana; Stéphane Paul; Qiang Pan-Hammarström; Lennart Hammarström; Annabelle Dupont; Alina Kurolap; Christine N Metz; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Fabio Ciceri; Lucila A Barreiros; Elena Dominguez-Garrido; Mateus Vidigal; Mayana Zatz; Diederik van de Beek; Sabina Sahanic; Ivan Tancevski; Yurii Stepanovskyy; Oksana Boyarchuk; Yoko Nukui; Miyuki Tsumura; Loreto Vidaur; Stuart G Tangye; Sonia Burrel; Darragh Duffy; Lluis Quintana-Murci; Adam Klocperk; Nelli Y Kann; Anna Shcherbina; Yu-Lung Lau; Daniel Leung; Matthieu Coulongeat; Julien Marlet; Rutger Koning; Luis Felipe Reyes; Angélique Chauvineau-Grenier; Fabienne Venet; Guillaume Monneret; Michel C Nussenzweig; Romain Arrestier; Idris Boudhabhay; Hagit Baris-Feldman; David Hagin; Joost Wauters; Isabelle Meyts; Adam H Dyer; Sean P Kennelly; Nollaig M Bourke; Rabih Halwani; Narjes Saheb Sharif-Askari; Karim Dorgham; Jérome Sallette; Souad Mehlal Sedkaoui; Suzan AlKhater; Raúl Rigo-Bonnin; Francisco Morandeira; Lucie Roussel; Donald C Vinh; Sisse Rye Ostrowski; Antonio Condino-Neto; Carolina Prando; Anastasiia Bonradenko; András N Spaan; Laurent Gilardin; Jacques Fellay; Stanislas Lyonnet; Kaya Bilguvar; Richard P Lifton; Shrikant Mane; Mark S Anderson; Bertrand Boisson; Vivien Béziat; Shen-Ying Zhang; Stéphanie Debette
Journal:  Sci Immunol       Date:  2021-08-19

6.  A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients.

Authors:  Mohammad Sadegh Soltani-Zangbar; Forough Parhizkar; Elham Ghaedi; Ali Tarbiat; Roza Motavalli; Amin Alizadegan; Leili Aghebati-Maleki; Davoud Rostamzadeh; Yousef Yousefzadeh; Golamreza Jadideslam; Sima Shahmohammadi Farid; Leila Roshangar; Ata Mahmoodpoor; Javad Ahmadian Heris; Abolfazl Miahipour; Mehdi Yousefi
Journal:  Cell Commun Signal       Date:  2022-07-16       Impact factor: 7.525

7.  Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus.

Authors:  Pragnesh Mistry; Shuichiro Nakabo; Liam O'Neil; Rishi R Goel; Kan Jiang; Carmelo Carmona-Rivera; Sarthak Gupta; Diana W Chan; Philip M Carlucci; Xinghao Wang; Faiza Naz; Zerai Manna; Amit Dey; Nehal N Mehta; Sarfaraz Hasni; Stefania Dell'Orso; Gustavo Gutierrez-Cruz; Hong-Wei Sun; Mariana J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-21       Impact factor: 11.205

8.  Autoantibodies against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis.

Authors:  Rui Xing; Lin Sun; Dong Wu; Yinji Jin; Changhong Li; Xiangyuan Liu; Jinxia Zhao
Journal:  Clin Rheumatol       Date:  2017-10-10       Impact factor: 2.980

9.  Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease.

Authors:  Justin A Jarrell; Matthew C Baker; Cory A Perugino; Hang Liu; Michelle S Bloom; Takashi Maehara; Heidi H Wong; Tobias V Lanz; Julia Z Adamska; Sarah Kongpachith; Jeremy Sokolove; John H Stone; Shiv S Pillai; William H Robinson
Journal:  J Allergy Clin Immunol       Date:  2021-05-08       Impact factor: 10.793

Review 10.  Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment.

Authors:  François Chasset; Jean-Michel Dayer; Carlo Chizzolini
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.